BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

  Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.

  September 27, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Why Medical Science Liaisons Should Earn Board Certification

  As MSLs take on greater roles in healthcare, standardization is crucial to fostering trust.

  September 27, 2023

   · 

  5 min read

   · 

  William Soliman
• 

  Drug Development

  Alto Reports Positive Phase II PTSD Data After Mid-Stage MDD Win

  Following promising results in major depressive disorder, Alto Neuroscience on Tuesday reported positive data for its investigational drug ALTO-100 in post-traumatic stress disorder.

  September 27, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Ahmed Mousa: From the Hill to the C-Suite

  As the incoming CEO of Vicore, Mousa is ready to rally for fresh investment to advance cures for respiratory conditions.

  September 27, 2023

   · 

  5 min read

   · 

  Karen Fischer
• 

  Policy

  BrainStorm Withdraws BLA for ALS Therapy, Plans Phase IIIb Trial

  After an FDA advisory committee voted 17-1 against approving NurOwn last month, BrainStorm executives Wednesday laid out a potential path forward for the experimental amyotrophic lateral sclerosis treatment.

  September 27, 2023

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Four Neurodegenerative Trials to Watch in Q4

  Pivotal clinical trials in Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis are expected to read out this fall. Here’s a closer look.

  September 27, 2023

   · 

  5 min read

   · 

  Stacy Kish
• 

  Policy

  AstraZeneca, BMS Reluctantly Agree to Medicare Drug Price Negotiation Program

  Despite filing respective lawsuits challenging the program, AstraZeneca and Bristol Myers Squibb have decided to participate in the first round of price negotiations under the Inflation Reduction Act.

  September 27, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?

  While Astellas did not say why it withdrew its suit, it was the only company to file a legal complaint that wasn’t on the initial IRA drug price negotiations list and may not have had any grounds to sue.

  September 27, 2023

   · 

  4 min read

   · 

  Nadia Bey
• 

  Drug Development

  Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data

  After picking up magrolimab in a $4.9 billion purchase of Forty Seven, a second Phase III study is being discontinued for the anti-CD47 antibody, this time in acute myeloid leukemia.

  September 27, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• Biotech Bay

  Blue Lake Biotechnology Presenting at Upcoming BioFuture and BIO Investor Forum Conferences

  Blue Lake Biotechnology, Inc. today announced that management will be presenting and engaging in 1-1 meetings at the following upcoming investor conferences.

  September 27, 2023

   · 

  1 min read